Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT536 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FT536 + pembrolizumab is an investigational combination therapy comprising FT536, an off-the-shelf, gene-edited, chimeric antigen receptor (CAR) natural killer (NK) cell therapy, and pembrolizumab, a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor monoclonal antibody. FT536 is derived from an induced pluripotent stem cell (iPSC) line and is engineered to target the α3 domain of MICA and MICB, stress ligands upregulated on many tumor cells to enable immune evasion. Additional genetic modifications include a modified CD16 receptor for enhanced engagement with tumor-targeting antibodies, IL-15 receptor fusion for increased NK activity, and CD38 knockout for improved persistence. Pembrolizumab blocks PD-1, restoring T cell function and enhancing antitumor immune response. The combination is being evaluated in Phase 1 studies for advanced solid tumors, leveraging both direct cytotoxicity (FT536) and relief of immune inhibition (pembrolizumab)[1][3][4].
- Other names
- FT536 plus pembrolizumabFT-536 plus pembrolizumabFT 536 plus pembrolizumabFT536 and pembrolizumabFT-536 and pembrolizumabFT 536 and pembrolizumab
02
Targets
MICB (Major histocompatibility complex class i-related protein B)PDCD1 (Programmed cell death protein 1 receptor)MICA (Major histocompatibility complex class I-related protein A)
Beyond the preview
Go deeper on FT536 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT536 + pembrolizumab.